Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CTX-8371 · 1 trial · 5 indications
Number of participants with dose limiting toxicities (DLTs), treatment-emergent adverse events (TEAEs), and/or changes in clinical laboratory abnormalities
Incidence of treatment-emergent adverse events (TEAEs)
| Arm | Type | Description |
|---|---|---|
| Dose Escalation Cohort 1 | EXPERIMENTAL | Escalating doses of CTX-8371 |
| Dose Expansion Cohort 2 | EXPERIMENTAL | Two CTX-8371 dose groups (3.0 mg/kg and 10.0 mg/kg) in three tumor type subgroups (NSCLC, TNBC, and HL) |
| Name | Type | Description |
|---|---|---|
| CTX-8371 | DRUG | Intravenous (IV) infusion every two weeks. |
Inclusion Criteria: 1. Age 18 years or older 2. Patients must have a histologically or cytologically confirmed diagnosis of locally advanced unresectable or metastatic disease that is relapsed/refractory to standard therapy or for which no effective standard therapy is available, including 1. M...
Top 20 of 84 competitors
CTX-8371 is an investigational small molecule being developed for the treatment of Non Small Cell Lung Cancer. It is currently in Phase 1 clinical development and is also being studied in other advanced malignancies, including Triple Negative Breast Cancer, Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma, and Malignant Melanoma.
CTX-8371 targets PD-L1, a protein involved in immune checkpoint regulation. By targeting PD-L1, CTX-8371 is designed to modulate the immune system's response to cancer cells. It is being evaluated in a Phase 1 clinical trial for its safety and efficacy in patients with advanced malignancies.
CTX-8371 is being developed by Compass Therapeutics, Inc., a biopharmaceutical company. Compass Therapeutics is publicly traded under the ticker symbol CMPX. The company is conducting a Phase 1 clinical trial to evaluate CTX-8371 in patients with advanced malignancies.
CTX-8371 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial is currently recruiting participants and is designed to evaluate the safety, tolerability, and preliminary efficacy of CTX-8371 in patients with advanced cancers.
CTX-8371 is being studied in a Phase 1 clinical trial with the identifier NCT06150664. This trial is titled 'A Phase 1 of CTX-8371 in Patients With Advanced Malignancies' and is currently recruiting participants in the United States. The trial has an enrollment target of 85 patients and includes conditions such as Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma, and Malignant Melanoma.
No, CTX-8371 is a unique investigational drug candidate developed by Compass Therapeutics. It is not known to be the same as any other approved or investigational drug. CTX-8371 is a small molecule that targets PD-L1 and is currently being evaluated in a Phase 1 clinical trial for advanced malignancies.